

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Cuttitta et al.

**Application No.** 10/529,116

**Filed:** March 24, 2005

**Confirmation No.** 6564

**For:** A NEW TARGET FOR ANGIOGENESIS  
AND ANTI-ANGIOGENESIS THERAPY

**Examiner:** Christine J. Saoud

**Art Unit:** 1647

**Attorney Reference No.** 4239-67026-06

**FILED VIA EFS**

COMMISSIONER FOR PATENTS  
FILED VIA ELECTRONIC FILING SYSTEM

**AMENDMENT AND RESPONSE TO NON-FINAL OFFICE ACTION**

This Amendment and Response to Non-Final Office Action is filed in answer to the non-final Office action, dated January 8, 2008, for which a three-month period for reply was set, making a response due on or before **April 8, 2008**. It is believed that no fees are required for this filing. In the event that fees are required, the Commissioner is authorized to charge any fees to deposit account 02-4550.

**An Amendment to the Specification** is on page 2.

**Amendments to the Claims** are reflected in the listing of claims that begins on page 3.

**Remarks** begin on page 5, and end with a **Conclusion** on page 8.

The **Declaration under 37 CFR § 1.132 of Frank Cuttitta, Ph.D.** is provided herewith, along with supporting Exhibits A and B (36 pages total).